TOI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TOI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. The Oncology Institute's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $7.9 Mil. The Oncology Institute's average total debt for the quarter that ended in Mar. 2024 was $119.8 Mil. Therefore, The Oncology Institute's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 6.63%.
The historical data trend for The Oncology Institute's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | - | 2.91 | 5.28 | 7.53 | 5.95 |
The Oncology Institute Quarterly Data | |||||||||||||||||||
Sep18 | Dec18 | Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 5.29 | 9.44 | 9.23 | -4.19 | 6.63 |
For the Medical Care Facilities subindustry, The Oncology Institute's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Effective Interest Rate on Debt % falls into.
The Oncology Institute's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2022 ) | + | Total Debt (A: Dec. 2023 )) | / count ) |
= | -1 * -6.777 | / | ( (108.179 | + | 119.675) | / 2 ) |
= | -1 * -6.777 | / | 113.927 | |||
= | 5.95 % |
where
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 102.681 | + | 5.498 |
= | 108.179 |
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 113.312 | + | 6.363 |
= | 119.675 |
The Oncology Institute's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Dec. 2023 ) | + | Total Debt (Q: Mar. 2024 )) | / count ) |
= | -1 * -7.94 | / | ( (119.675 | + | 119.835) | / 2 ) |
= | -1 * -7.94 | / | 119.755 | |||
= | 6.63 % |
where
Total Debt (Q: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 113.312 | + | 6.363 |
= | 119.675 |
Total Debt (Q: Mar. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 113.445 | + | 6.39 |
= | 119.835 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
The Oncology Institute (NAS:TOI) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of The Oncology Institute's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Havencrest Healthcare Partners, L.p. | 10 percent owner | 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039 |
Mihir Shah | officer: Chief Financial Officer, other: Principal Financial Officer | C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801 |
Brad Hively | director, officer: Chief Executive Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Jeremy Castle | officer: Chief Operating Officer | 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richard A Barasch | director, officer: Executive Chairman | C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573 |
Matthew P Miller | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Daniel Virnich | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Yale Podnos | officer: Chief Medical Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Diona Simoneit | officer: Chief Accounting Officer, other: Principal Accounting Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mohit Kaushal | director | 44 SOUTH BROADWAY, WHITE PLAINS NY 10601 |
Gabriel Ling | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mark L Pacala | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richy Agajanian | 10 percent owner | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Maeve O'meara | director | C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105 |
Toi Hc I, Llc | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201 |
From GuruFocus
By PRNewswire PRNewswire • 05-04-2023
By PurpleRose PurpleRose • 08-09-2022
By sperokesalga sperokesalga • 06-12-2023
By Value_Insider Value_Insider • 12-19-2022
By Value_Insider Value_Insider • 10-17-2022
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 07-18-2023
By Value_Insider Value_Insider • 11-22-2022
By Marketwired • 07-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.